LIGAND PHARMACEUTICALS INC (LGNDZ)
2025-06-30 | ||||
|---|---|---|---|---|
| Total revenues and other income | 47,627 | |||
| Research and development | 6,567 | |||
| Financial royalty assets impairment | - | |||
| General and administrative | 20,175 | |||
| Fair value adjustments to partner program derivatives | -1,276 | |||
| Amortization of intangibles | 8,258 | |||
| Cost of captisol | 2,907 | |||
| Total operating costs and expenses | 39,183 | |||
| Operating income (loss) | 8,444 | |||
| Other non-operating expense, net | 1,372 | |||
| Interest income | 1,621 | |||
| Interest expense | 1,153 | |||
| Gain (loss) from short-term investments | 939 | |||
| Total non-operating income (expenses), net | 2,779 | |||
| Income (loss) before income taxes | 11,223 | |||
| Income tax (expense) benefit | 6,376 | |||
| Net income (loss) | 4,847 | |||
| Basic net income (loss) per share (in usd per share) | 0.25 | |||
| Diluted net income (loss) per share (in usd per share) | 0.24 | |||
| Shares used in basic per share calculation (in shares) | 19,327,000 | |||
| Shares used in diluted per share calculation (in shares) | 19,926,000 | |||